X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs GSK PHARMA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD GSK PHARMA STRIDES SHASUN LTD/
GSK PHARMA
 
P/E (TTM) x 13.9 63.7 21.8% View Chart
P/BV x 1.6 10.2 15.8% View Chart
Dividend Yield % 0.6 1.2 49.6%  

Financials

 STRIDES SHASUN LTD   GSK PHARMA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
GSK PHARMA
Mar-17
STRIDES SHASUN LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2753,838 33.2%   
Low Rs9182,637 34.8%   
Sales per share (Unadj.) Rs389.6354.2 110.0%  
Earnings per share (Unadj.) Rs28.039.8 70.3%  
Cash flow per share (Unadj.) Rs48.942.9 114.1%  
Dividends per share (Unadj.) Rs4.5030.00 15.0%  
Dividend yield (eoy) %0.40.9 44.3%  
Book value per share (Unadj.) Rs303.1236.9 127.9%  
Shares outstanding (eoy) m89.4284.70 105.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.89.1 30.8%   
Avg P/E ratio x39.281.4 48.1%  
P/CF ratio (eoy) x22.475.5 29.7%  
Price / Book Value ratio x3.613.7 26.5%  
Dividend payout %16.175.4 21.3%   
Avg Mkt Cap Rs m98,036274,216 35.8%   
No. of employees `0005.84.7 123.5%   
Total wages/salary Rs m5,8814,830 121.8%   
Avg. sales/employee Rs Th6,005.96,387.0 94.0%   
Avg. wages/employee Rs Th1,014.01,028.3 98.6%   
Avg. net profit/employee Rs Th431.2717.1 60.1%   
INCOME DATA
Net Sales Rs m34,83430,000 116.1%  
Other income Rs m1,686728 231.5%   
Total revenues Rs m36,52030,728 118.8%   
Gross profit Rs m6,4284,190 153.4%  
Depreciation Rs m1,872263 711.6%   
Interest Rs m2,2690-   
Profit before tax Rs m3,9734,655 85.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,006457 -220.1%   
Tax Rs m4701,744 26.9%   
Profit after tax Rs m2,5013,368 74.3%  
Gross profit margin %18.514.0 132.1%  
Effective tax rate %11.837.5 31.6%   
Net profit margin %7.211.2 63.9%  
BALANCE SHEET DATA
Current assets Rs m38,16516,742 228.0%   
Current liabilities Rs m30,4027,202 422.1%   
Net working cap to sales %22.331.8 70.1%  
Current ratio x1.32.3 54.0%  
Inventory Days Days7752 149.3%  
Debtors Days Days10421 502.7%  
Net fixed assets Rs m37,6398,635 435.9%   
Share capital Rs m894847 105.6%   
"Free" reserves Rs m26,21019,222 136.4%   
Net worth Rs m27,10520,069 135.1%   
Long term debt Rs m16,37710 163,771.0%   
Total assets Rs m81,16830,038 270.2%  
Interest coverage x2.8NM-  
Debt to equity ratio x0.60 121,258.4%  
Sales to assets ratio x0.41.0 43.0%   
Return on assets %5.911.2 52.4%  
Return on equity %9.216.8 55.0%  
Return on capital %12.125.5 47.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,465528 2,550.2%   
Fx outflow Rs m4,0767,193 56.7%   
Net fx Rs m9,389-6,665 -140.9%   
CASH FLOW
From Operations Rs m2,8812,360 122.1%  
From Investments Rs m-7,0513,008 -234.4%  
From Financial Activity Rs m3,382-5,108 -66.2%  
Net Cashflow Rs m-788260 -302.6%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 37.8 10.2 370.6%  
FIIs % 8.6 23.8 36.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 15.4 168.2%  
Shareholders   56,241 102,036 55.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare STRIDES SHASUN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and consumer durables sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Feb 20, 2018 01:21 PM

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS